Time filter

Source Type

Zwaan C.M.,Sophia Childrens Hospital Erasmus MC | Zwaan C.M.,International Berlin Frankfurt Munster Study Group I BFM SG New Agents Committee | Zwaan C.M.,Dutch Childhood Oncology Group | Kolb E.A.,Nemours Alfred I Du Pont Hospital For Children | And 37 more authors.
Journal of Clinical Oncology | Year: 2015

Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid leukemia (AML) have made enormous progress during the past decades. Because AML is a rare type of childhood cancer, with an incidence of approximately seven occurrences per 1 million children annually, national and international collaborative efforts have evolved. This overview describes these efforts and includes a summary of the history and contributions of each of the main collaborative pediatric AML groups worldwide. The focus is on translational and clinical research, which includes past, current, and future clinical trials. Separate sections concern acute promyelocytic leukemia, myeloid leukemia of Down syndrome, and relapsed AML. A plethora of novel antileukemic agents that have emerged, including new classes of drugs, are summarized as well. Finally, an important aspect of the treatment of pediatric AML - supportive care - and late effects are discussed. The future is bright, with a wide range of emerging innovative therapies and with more and more international collaboration that ultimately aim to cure all children with AML, with fewer adverse effects and without late effects. © 2015 by American Society of Clinical Oncology.

Loading I BFM AcuteMyeloid Leukemia AML Study Group collaborators
Loading I BFM AcuteMyeloid Leukemia AML Study Group collaborators